JP2018138603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018138603A5 JP2018138603A5 JP2018093590A JP2018093590A JP2018138603A5 JP 2018138603 A5 JP2018138603 A5 JP 2018138603A5 JP 2018093590 A JP2018093590 A JP 2018093590A JP 2018093590 A JP2018093590 A JP 2018093590A JP 2018138603 A5 JP2018138603 A5 JP 2018138603A5
- Authority
- JP
- Japan
- Prior art keywords
- complement inhibitor
- complement
- chronic
- compstatin
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161499895P | 2011-06-22 | 2011-06-22 | |
| US61/499,895 | 2011-06-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517223A Division JP6618682B2 (ja) | 2011-06-22 | 2012-06-22 | 補体阻害剤による慢性障害の治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218474A Division JP2020045361A (ja) | 2011-06-22 | 2019-12-03 | 補体阻害剤による慢性障害の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018138603A JP2018138603A (ja) | 2018-09-06 |
| JP2018138603A5 true JP2018138603A5 (https=) | 2018-12-27 |
Family
ID=47422981
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517223A Active JP6618682B2 (ja) | 2011-06-22 | 2012-06-22 | 補体阻害剤による慢性障害の治療方法 |
| JP2018093590A Pending JP2018138603A (ja) | 2011-06-22 | 2018-05-15 | 補体阻害剤による慢性障害の治療方法 |
| JP2019218474A Pending JP2020045361A (ja) | 2011-06-22 | 2019-12-03 | 補体阻害剤による慢性障害の治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517223A Active JP6618682B2 (ja) | 2011-06-22 | 2012-06-22 | 補体阻害剤による慢性障害の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019218474A Pending JP2020045361A (ja) | 2011-06-22 | 2019-12-03 | 補体阻害剤による慢性障害の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US10039802B2 (https=) |
| EP (2) | EP3524258B1 (https=) |
| JP (3) | JP6618682B2 (https=) |
| CN (1) | CN103796667A (https=) |
| AU (3) | AU2012272706B2 (https=) |
| BR (1) | BR112013033272A2 (https=) |
| CA (1) | CA2840270C (https=) |
| ES (1) | ES3044832T3 (https=) |
| IL (2) | IL229950B (https=) |
| MX (2) | MX379206B (https=) |
| WO (1) | WO2012178083A1 (https=) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| MX356528B (es) | 2011-05-11 | 2018-06-01 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y usos de los mismos. |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| CA2847862C (en) | 2011-09-07 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with improved pharmacokinetic properties |
| US9579360B2 (en) * | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| MX366404B (es) | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| CA2909706C (en) * | 2013-04-17 | 2023-02-14 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
| SG10201804960RA (en) | 2013-12-12 | 2018-07-30 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| US9732103B2 (en) | 2014-02-25 | 2017-08-15 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders |
| EP3130587B1 (en) | 2014-03-31 | 2021-06-16 | NOF Corporation | Hydrophilic polymer derivative having cyclic benzylidene acetal linker |
| CN106661629B (zh) * | 2014-08-07 | 2021-03-16 | 深圳华大基因科技有限公司 | 筛选纳米抗体的方法及系统 |
| CN107250798A (zh) * | 2014-12-05 | 2017-10-13 | 雀巢产品技术援助有限公司 | 用于检测患者样品中的生物制品的间接均相迁移率变动试验 |
| US11840564B2 (en) * | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035362A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| US11903994B2 (en) * | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| AU2016344133A1 (en) * | 2015-10-30 | 2018-05-17 | Genentech, Inc. | Anti-Factor D antibody formulations |
| WO2017127761A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| MX2018011648A (es) * | 2016-03-31 | 2019-01-30 | Omeros Corp | Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo. |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| CN107019793B (zh) * | 2017-02-27 | 2019-12-24 | 新乡医学院 | MBL在制备预防或治疗Th17细胞引发疾病药物中的应用 |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| IL269844B2 (en) | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| WO2018193120A1 (en) * | 2017-04-21 | 2018-10-25 | Volution Immuno Pharmaceuticals Sa | Coversin for the treatment of cicatrising eye inflammatory disorders |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| US11730792B2 (en) | 2017-04-21 | 2023-08-22 | Volution Immuno Pharmaceuticals Sa | Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) |
| WO2019022986A1 (en) * | 2017-07-24 | 2019-01-31 | Vitrisa Therapeutics, Inc. | NUCLEIC ACID COMPOSITIONS AND METHODS OF INHIBITING D-FACTOR |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| CN107463795A (zh) * | 2017-08-02 | 2017-12-12 | 南昌大学 | 一种识别酪氨酸翻译后修饰位点的预测算法 |
| WO2019089653A1 (en) * | 2017-10-30 | 2019-05-09 | Apellis Pharmaceuticals, Inc. | Treatment of disorders |
| US12037389B2 (en) | 2017-12-01 | 2024-07-16 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| EP4011905A3 (en) | 2018-04-06 | 2022-06-29 | The Trustees Of The University Of Pennsylvania | Compstatin analogs with increased solubility and improved pharmacokinetic properties |
| CN109078168B (zh) * | 2018-07-26 | 2019-09-06 | 广西医科大学第一附属医院 | 靶向补体抑制剂在制备改善脑死亡供肝药物中的应用 |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| WO2020051538A1 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| KR20210093855A (ko) | 2018-09-25 | 2021-07-28 | 아칠리온 파르마세우티칼스 인코포레이티드 | 보체 인자 d 억제제의 형태체 형태 |
| WO2020131974A1 (en) | 2018-12-17 | 2020-06-25 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| BR112021018456A2 (pt) | 2019-03-22 | 2021-11-23 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento |
| WO2021081026A1 (en) | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| JP2023523790A (ja) | 2020-04-30 | 2023-06-07 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法 |
| US20230172930A1 (en) | 2020-05-12 | 2023-06-08 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| US11918624B2 (en) | 2020-06-10 | 2024-03-05 | Kelsius Laboratories LLC | Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| EP4274896A1 (en) | 2021-01-05 | 2023-11-15 | Alnylam Pharmaceuticals, Inc. | Complement component 9 (c9) irna compositions and methods of use thereof |
| JP2024535850A (ja) | 2021-09-17 | 2024-10-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法 |
| CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
| WO2025245166A1 (en) * | 2024-05-20 | 2025-11-27 | New York University | Biomarkers for xenograft rejection |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US22260A (en) | 1858-12-07 | Improvement in saw-sets | ||
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| US5157110A (en) | 1988-08-20 | 1992-10-20 | The Government Of The United States Of America | Synthetic, anti-complement protein |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| EP1413587A2 (en) | 1991-05-03 | 2004-04-28 | Washington University | Modified complement system regulator |
| US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| US5776970A (en) | 1994-04-28 | 1998-07-07 | Yeda Research And Development Co. Ltd. | Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6319897B1 (en) | 1996-03-13 | 2001-11-20 | John D. Lambris | Peptides which inhibit complement activation |
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| WO1997047321A1 (en) | 1996-06-14 | 1997-12-18 | The Johns Hopkins University School Of Medicine | Use of chimeric vaccinia virus complement control proteins to inhibit complement |
| JPH1087700A (ja) | 1996-06-17 | 1998-04-07 | Smithkline Beecham Corp | Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法 |
| AU6957098A (en) | 1997-04-11 | 1998-11-11 | Advanced Medicine, Inc. | Polyvalent presenter combinatorial libraries and their uses |
| JP2002503223A (ja) | 1997-04-11 | 2002-01-29 | アドバンスト・メディシン・インコーポレイテッド | 複数の活性分子を供与する分子 |
| US6676943B1 (en) | 1997-04-24 | 2004-01-13 | Regents Of The University Of Minnesota | Human complement C3-degrading protein from Streptococcus pneumoniae |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| NZ503033A (en) | 1997-08-26 | 2003-01-31 | Gliatech Inc | Inhibition of complement activation using anti-properdin agents |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| AU3485999A (en) | 1998-04-10 | 1999-11-01 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| US6492403B1 (en) | 1999-02-09 | 2002-12-10 | 3-Dimensional Pharmaceuticals, Inc. | Methods of treating C1s-mediated diseases and conditions and compositions thereof |
| AU4369000A (en) | 1999-04-26 | 2000-11-10 | Duke University | Inhibition of complement action |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| US6998468B2 (en) | 2000-03-23 | 2006-02-14 | Tanox, Inc. | Anti-C2/C2a inhibitors of complement activation |
| WO2002010388A2 (en) | 2000-08-01 | 2002-02-07 | Amgen Inc. | C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| EP2896631A1 (en) | 2000-10-10 | 2015-07-22 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| JP2005504715A (ja) | 2000-12-29 | 2005-02-17 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続放出特性を有する吸入用粒子 |
| US7138530B2 (en) | 2002-05-28 | 2006-11-21 | 3-Dimensional Pharmaceuticals, Inc. | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| AU2003276131A1 (en) | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| PT1549333E (pt) | 2002-09-20 | 2012-01-03 | Univ Pennsylvania | Análogos de compstatina com actividade melhorada |
| EP1613642A4 (en) | 2003-04-16 | 2008-07-02 | Texas A & M Univ Sys | EFB PROTEIN OF STAPHYLOCOCCUS AUREUS AND C3 BINDING STAGE THAT INHIBITS COMPLEMENTAL ACTIVATION |
| EP1629098B1 (en) | 2003-06-02 | 2009-04-01 | Varleigh Limited | Complement inhibitors from ticks |
| EP1498422A1 (de) | 2003-07-17 | 2005-01-19 | Jerini AG | C5a-Rezeptor-Antagonisten |
| US7489726B2 (en) | 2003-08-13 | 2009-02-10 | Mitsubishi Electric Research Laboratories, Inc. | Resource-constrained sampling of multiple compressed videos |
| US7322498B2 (en) | 2003-09-10 | 2008-01-29 | The Ergo Baby Carrier, Inc. | Baby carrier |
| CA2579635A1 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| JP4960096B2 (ja) * | 2003-09-22 | 2012-06-27 | ペントラコール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−６の生物学的効果を減じる化合物の使用 |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| HUE038239T2 (hu) | 2004-02-12 | 2018-10-29 | Archemix Llc | Komplementrendszerrel összefüggõ rendellenességek kezelésében alkalmazható aptamer terapeutikumok |
| JP4906715B2 (ja) | 2004-05-08 | 2012-03-28 | ニューロジェン・コーポレーション | ４，５−ジ置換−２−アリールピリミジン類 |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006042252A2 (en) | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| EP1861114B1 (en) | 2005-03-11 | 2011-02-02 | Potentia Pharmaceuticals, Inc. | Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration |
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| CA2654440C (en) * | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007034277A1 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Aryl substituted imidazo [4,5-c] pyridine compounds as c3a receptor antagonists |
| WO2007034278A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Fused imidazole derivatives as c3a receptor antagonists |
| WO2007034282A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists |
| EP2662089A3 (en) | 2005-10-08 | 2014-02-19 | Potentia Pharmaceuticals, Inc. | Compstatin and analogs thereof for eye disorders |
| CN102977191B (zh) | 2005-11-28 | 2016-08-10 | 宾夕法尼亚州大学理事会 | 有效的c3补体抑制素类似物 |
| US20100119530A1 (en) * | 2006-07-06 | 2010-05-13 | Wenchao Song | Regulation of TLR Signaling by Complement |
| US20080188528A1 (en) | 2006-12-22 | 2008-08-07 | Biediger Ronald J | Modulators of C3a receptor and methods of use thereof |
| HUE026001T2 (en) | 2007-02-05 | 2016-04-28 | Apellis Pharmaceuticals Inc | Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system |
| CA2679400A1 (en) * | 2007-02-28 | 2008-09-04 | Schering Corporation | Combination therapy for treatment of immune disorders |
| JP5332064B2 (ja) * | 2007-03-01 | 2013-11-06 | ウェルスタット イムノセラピューティクス， エルエルシー | 炎症により特徴付けられる疾患の治療 |
| US9540427B2 (en) | 2007-05-30 | 2017-01-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Peptide-based stat inhibitor |
| US20090048295A1 (en) | 2007-08-13 | 2009-02-19 | Joseph Kent Barbay | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
| CN101970002B (zh) | 2007-08-27 | 2016-05-18 | 诺福麦德治疗学股份有限公司 | 用因子Bb特异性抗体抑制补体活化的方法 |
| BRPI0817524A2 (pt) | 2007-10-02 | 2017-05-02 | Potentia Pharmaceuticals Inc | liberação prolongada de análogos de compstatina provenientes de géis |
| WO2009092087A2 (en) * | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| DK2262831T3 (en) | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| CA2742802C (en) * | 2008-11-10 | 2019-11-26 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| RS54998B1 (sr) | 2008-12-22 | 2016-11-30 | Chemocentryx Inc | Antagonisti c5ar |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| CA2760839C (en) * | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| WO2010135717A2 (en) | 2009-05-21 | 2010-11-25 | Potentia Pharmaceuticals, Inc. | Complement assays and uses thereof |
| CA2766565A1 (en) | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| US20130046015A1 (en) * | 2010-02-11 | 2013-02-21 | Robert C. Axtell | Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease |
| US8625635B2 (en) | 2010-04-26 | 2014-01-07 | Cleversafe, Inc. | Dispersed storage network frame protocol header |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| ES2688589T3 (es) * | 2010-07-21 | 2018-11-05 | Eastern Virginia Medical School | Compuestos peptídicos para regular el sistema del complemento |
| EP2640745B1 (en) * | 2010-09-10 | 2018-11-07 | MedImmune Limited | Bivalent and bispecific anti-il6/anti-il23 antibodies |
| CA2813049A1 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| WO2014099546A1 (en) | 2012-12-19 | 2014-06-26 | Promerus, Llc | Process for the preparation of high purity norbornene alkanols and derivatives thereof |
| CA2920293A1 (en) * | 2013-08-16 | 2015-02-19 | Alexion Pharmaceuticals, Inc. | Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant |
| US9806963B2 (en) | 2013-10-18 | 2017-10-31 | Cellco Partnership | Feature activation on device |
| JP6815852B2 (ja) | 2016-11-30 | 2021-01-20 | Ntn株式会社 | 電動アクチュエータ用回転駆動源および電動アクチュエータ |
-
2012
- 2012-06-22 EP EP18212739.9A patent/EP3524258B1/en active Active
- 2012-06-22 MX MX2019003528A patent/MX379206B/es unknown
- 2012-06-22 CA CA2840270A patent/CA2840270C/en active Active
- 2012-06-22 WO PCT/US2012/043845 patent/WO2012178083A1/en not_active Ceased
- 2012-06-22 ES ES18212739T patent/ES3044832T3/es active Active
- 2012-06-22 MX MX2013014756A patent/MX363606B/es unknown
- 2012-06-22 EP EP12803380.0A patent/EP2723361B1/en active Active
- 2012-06-22 JP JP2014517223A patent/JP6618682B2/ja active Active
- 2012-06-22 US US14/128,447 patent/US10039802B2/en active Active
- 2012-06-22 AU AU2012272706A patent/AU2012272706B2/en active Active
- 2012-06-22 CN CN201280036308.0A patent/CN103796667A/zh active Pending
- 2012-06-22 BR BR112013033272-7A patent/BR112013033272A2/pt not_active Application Discontinuation
-
2013
- 2013-12-17 IL IL22995013A patent/IL229950B/en active IP Right Grant
-
2017
- 2017-09-27 AU AU2017235936A patent/AU2017235936B2/en active Active
-
2018
- 2018-05-15 JP JP2018093590A patent/JP2018138603A/ja active Pending
- 2018-06-29 US US16/023,383 patent/US20190192617A1/en not_active Abandoned
-
2019
- 2019-11-04 IL IL270406A patent/IL270406B/en unknown
- 2019-11-19 AU AU2019268066A patent/AU2019268066A1/en not_active Abandoned
- 2019-12-03 JP JP2019218474A patent/JP2020045361A/ja active Pending
- 2019-12-13 US US16/714,252 patent/US11013782B2/en active Active
-
2021
- 2021-04-20 US US17/235,281 patent/US11712460B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018138603A5 (https=) | ||
| JP2016518387A5 (https=) | ||
| JP2012193216A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| JP2018515557A5 (https=) | ||
| JP2018111728A5 (https=) | ||
| JP2017158561A5 (https=) | ||
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JP2017528483A5 (https=) | ||
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2009008051A (es) | Regimen posologico para inhibidores de comt. | |
| JP2015504871A5 (https=) | ||
| EA201792592A1 (ru) | Фармацевтические препараты, содержащие тенофовир и эмтрицитабин | |
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| MX2016009427A (es) | Formulaciones de pridopidina de liberacion modificada. | |
| JP2017160178A5 (https=) | ||
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990425A1 (ru) | Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2017503014A5 (https=) | ||
| JP2017507142A5 (https=) | ||
| ZA201901370B (en) | Formulations for oral administration of active agents | |
| JP2017512194A5 (https=) |